The existence of KEAP1 or NRF2 mutations in patients with non-small cell lung cancer was correlated with poor responses to chemotherapy, suggesting that NRF2 activation causes resistance to therapeutic intervention. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.